Respiratory Fluoroquinolone May Increase the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis
Among patients on receiving hemodialysis (HD), treatment with fluoroquinolone may be linked with an augmented risk of sudden cardiac death (SCD) when compared to treatment with an amoxicillin-based antibiotic, according to a study published in JAMA Cardiology. “Respiratory fluoroquinolone antibiotics are some of the most common medications with QT interval–prolonging potential prescribed to patients with hemodialysis-dependent kidney failure—individuals who have a very high risk of SCD. To date, there have been no large-scale, population-specific studies evaluating the cardiac safety of respiratory fluoroquinolones in the hemodialysis population,” the researchers wrote.
If you’re older and your legs ache, it could be nothing — or it could be a sign of peripheral artery disease (PAD). Have you ever even heard of it? Maybe not. That’s why the Society for Vascular Surgery would like you to know a little more.
“As we age, we are susceptible to some aches and pains, possibly a tightness in the lower back after standing for long periods of time or a soreness in the legs after a challenging workout, but if unexplained pain persists, it’s important to see a physician,” said Dr. Alan Dietzek, a surgeon in Danbury, Conn. “Of course, not all pain indicates a serious problem, but certain leg pain and other symptoms in the lower extremities could be a sign of PAD.” Peripheral artery disease happens when plaque builds up in the arteries of the legs. This happens gradually. If it’s allowed to progress, it can limit or block blood flow in that artery.
Patients with atrial fibrillation (AFib) cite multiple reasons for nonadherence to direct-acting oral anticoagulant (DOAC) therapy, according to a study published online in the Journal of the American Geriatrics Society.
Derjung M. Tarn, MD, PhD, from the University of California at Los Angeles, and colleagues sought to understand the reasons patients with AF are nonadherent to apixaban, the most often-prescribed DOAC, through semistructured telephone interviews with 42 patients with documented nonadherence to apixaban.
“In conclusion, this study describes patient-reported reasons underlying nonadherence to the DOAC apixaban that include cost, concerns about bleeding, uncertainty about the need for anticoagulation, and beliefs that skipping doses is inconsequential,” the authors write. “Patients did not always tell their physicians about their nonadherence. This work identifies targets for interventions to increase adherence.”